AllianceBernstein’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

AllianceBernstein’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-666,227	Closed	-$16.1M	–	3335
2023 Q1	$16.1M	Buy	666,227 +574,627	+627%	+$7.21M	0.01%	916
2022 Q4	$968K	Hold	91,600	–	–	﹤0.01%	2297
2022 Q3	$412K	Buy	91,600 +4,700	+5%	+$21.4K	﹤0.01%	2736
2022 Q2	$348K	Hold	86,900	–	–	﹤0.01%	2831
2022 Q1	$636K	Buy	86,900 +300	+0.3%	+$1.79K	﹤0.01%	2580
2021 Q4	$487K	Hold	86,600	–	–	﹤0.01%	2756
2021 Q3	$554K	Hold	86,600	–	–	﹤0.01%	2715
2021 Q2	$730K	Buy	86,600 +43,400	+100%	+$350K	﹤0.01%	2656
2021 Q1	$453K	Sell	43,200 -9,300	-18%	-$131K	﹤0.01%	2700
2020 Q4	$889K	Hold	52,500	–	–	﹤0.01%	2343
2020 Q3	$674K	Sell	52,500 -1,900	-3%	-$24K	﹤0.01%	2371
2020 Q2	$768K	Buy	+54,400	New	+$687K	﹤0.01%	2349

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein's PRVB Position: Q2 2023 in Review

AllianceBernstein sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 666,227 shares — an estimated $16.1M sold.

AllianceBernstein first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $16.1M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

AllianceBernstein reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AllianceBernstein sold 666,227 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $16.1M.
AllianceBernstein first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
AllianceBernstein's Provention Bio, Inc. Common Stock position peaked at $16.1M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.